Sunesis to Present at ROTH 23rd Annual OC Growth Stock Conference
09 Marzo 2011 - 1:29PM
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) a biopharmaceutical
company focused on the development and commercialization of new
oncology therapeutics for the treatment of solid and hematologic
cancers, today announced that Senior Vice President of Corporate
Development & Finance and Chief Financial Officer, Eric
Bjerkholt, will be presenting at the ROTH 23rd Annual OC Growth
Stock Conference on Monday, March 14th at 3:30 PM Pacific Time
(6:30 PM Eastern Time), at The Ritz Carlton in Laguna Niguel,
California. This presentation will not be webcast.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the
development and commercialization of new oncology therapeutics for
the treatment of solid and hematologic cancers. Sunesis has built a
highly experienced cancer drug development organization committed
to advancing its lead product candidate, vosaroxin, in multiple
indications to improve the lives of people with cancer. For
additional information on Sunesis, please visit
http://www.sunesis.com.
SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals,
Inc.
The Sunesis Pharmaceuticals, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8773
CONTACT: Andrea Rabney
Argot Partners
212-600-1902
Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717
Grafico Azioni Sunesis Pharmaceuticals, Inc. (MM) (NASDAQ:SNSSD)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Sunesis Pharmaceuticals, Inc. (MM) (NASDAQ:SNSSD)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Sunesis Pharmaceuticals, Inc. (MM) (NASDAQ): 0 articoli recenti
Più Sunesis Pharmaceuticals, Inc. Articoli Notizie